Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
Public ClinicalTrials.gov record NCT02603705. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
Study identification
- NCT ID
- NCT02603705
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 281 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2016 (Actual)
- Primary completion
- Jun 15, 2017 (Actual)
- Completion
- Jun 15, 2017 (Actual)
- Last update posted
- Mar 5, 2018
2016 – 2017
United States locations
- U.S. sites
- 39
- U.S. states
- 22
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 334 | Huntsville | Alabama | 35801 | — |
| Site 328 | Tucson | Arizona | 85712 | — |
| Site 332 | Jacksonville | Florida | 32257 | — |
| Site 340 | Miami Gardens | Florida | 33169 | — |
| Site 320 | Plantation | Florida | 33317 | — |
| Site 302 | Tampa | Florida | 33603 | — |
| Site 315 | Tampa | Florida | 33613 | — |
| Site 310 | Winter Haven | Florida | 33880 | — |
| Site 316 | Dawsonville | Georgia | 30534 | — |
| Site 311 | Marietta | Georgia | 30060 | — |
| Site 336 | Bloomington | Illinois | 61701 | — |
| Site 345 | Blue Island | Illinois | 60406 | — |
| Site 304 | Evansville | Indiana | 47714 | — |
| Site 325 | Valparaiso | Indiana | 46383 | — |
| Site 321 | Overland Park | Kansas | 66210 | — |
| Site 342 | Wichita | Kansas | 67205 | — |
| Site 329 | New Orleans | Louisiana | 70114 | — |
| Site 326 | Quincy | Massachusetts | 02169 | — |
| Site 303 | St Louis | Missouri | 63141 | — |
| Site 306 | Las Vegas | Nevada | 89119 | — |
| Site 313 | Belvidere | New Jersey | 07823 | — |
| Site 346 | Blackwood | New Jersey | 08012 | — |
| Site 323 | Hartsdale | New York | 10530 | — |
| Site 338 | Mooresville | North Carolina | 28117 | — |
| Site 333 | Cincinnati | Ohio | 45212 | — |
| Site 343 | Cleveland | Ohio | 44122 | — |
| Site 308 | Huber Heights | Ohio | 45424 | — |
| Site 347 | Kettering | Ohio | 45429 | — |
| Site 335 | Oklahoma City | Oklahoma | 73112 | — |
| Site 312 | Eugene | Oregon | 97401 | — |
| Site 322 | Duncansville | Pennsylvania | 16635 | — |
| Site 324 | Wyomissing | Pennsylvania | 19610 | — |
| Site 344 | Myrtle Beach | South Carolina | 29588 | — |
| Site 314 | Summerville | South Carolina | 29485 | — |
| Site 341 | New Tazewell | Tennessee | 37825 | — |
| Site 318 | Austin | Texas | 78731 | — |
| Site 330 | Dallas | Texas | 75231 | — |
| Site 309 | San Antonio | Texas | 78218 | — |
| Site 331 | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02603705, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2018 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02603705 live on ClinicalTrials.gov.